Clinical Trial

PALbociclib Endocrine Therapy Followed by Talazo Vs. Talazoz-Atezo Study

Study acronym: Young-PALETTA
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated January 3, 2025 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is a prospective, two-arm, randomized phase II study of talazoparib versus talazoparib plus atezolizumab in ER+ premeonopausal women with metastatic breast cancer harboring HRD scar 1st line treatment: GnRH agonist + Aromatase Inhibitor(AI) + Palbociclib 28 days after the last treatment of 1st line treatment(., randomization for 2nd line treatment is conducte to arm A(Talazoparib+Atezolizumab) and arm B(Talazoparib monotherapy)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-03-25; most recent amendment 2025-01-01.
Status change: Not Yet Recruiting → Recruiting 2025-01-01
Trial Details
NCT Number NCT04819243
Lead Sponsor Samsung Medical Center
Conditions Premenopausal HR+/HER2- Metastatic Breast Cancer
Enrollment 178 participants
Start Date 2021-08-25
Primary Completion 2025-12-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-01-03